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Abstract
Background: Aβ deposits in the brains of patients with Alzheimer's disease (AD) are closely associated
with innate immune responses such as activated microglia and increased cytokines. Accumulating evidence
supports the hypothesis that innate immune/inflammatory responses play a pivotal role in the pathogenesis
of AD: either beneficial or harmful effects on the AD progression. The molecular mechanisms by which
the innate immune system modulates the AD progression are not well understood. Toll-like receptors
(TLRs) are first-line molecules for initiating the innate immune responses. When activated through TLR
signaling, microglia respond to pathogens and damaged host cells by secreting chemokines and cytokines
and express the co-stimulatory molecules needed for protective immune responses to pathogens and
efficient clearance of damaged tissues. We previously demonstrated that an AD mouse model homozygous
for a destructive mutation of TLR4 has increases in diffuse and fibrillar Aβ deposits as well as buffer-soluble
and insoluble Aβ in the brain as compared with a TLR4 wild-type AD mouse model. Here, we investigated
the roles of TLR4 in Aβ-induced upregulation of cytokines and chemokines, Aβ-induced activation of
microglia and astrocytes and Aβ-induced immigration of leukocytes.
Methods: Using the same model, levels of cytokines and chemokines in the brain were determined by
multiplex cytokine/chemokine array. Activation of microglia and astrocytes and immigration of leukocytes
were determined by immunoblotting and immunohistochemistry followed by densitometry and
morphometry, respectively.
Results: Levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-10 and IL-17 in the brains of
TLR4 wild-type AD mice were significantly higher than those in TLR4 wild-type non-transgenic littermates.
Such increases in cytokines were not found in TLR4 mutant AD mice as compared with TLR4 mutant non-
transgenic littermates. Although expression levels of CD11b (a microglia marker) and GFAP (a reactive
astrocyte marker) in the brains of TLR4 mutant AD mice were higher than those in TLR4 wild type AD
mice, no difference was found in levels of CD45 (common leukocyte antigen).
Conclusion: This is the first demonstration of TLR4-dependent upregulation of cytokines in an AD
mouse model. Our results suggest that TLR4 signaling is involved in AD progression and that TLR4
signaling can be a new therapeutic target for AD.
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Background
Patients with Alzheimer's disease (AD) develop deposits
of aggregated amyloid β-protein (Aβ) in neuritic plaques
and cerebral vessels (cerebrovascular amyloid angiopa-
thy). Fibrillar Aβ deposits in AD brain are accompanied by
innate immune responses such as activated microglia and
increased levels of cytokines [1]. Earlier studies indicated
that the deposition of Aβ in the brain might activate
microglia, initiating a proinflammatory cascade that
resulted in the release of potentially cytotoxic molecules,
cytokines, complements, proteases and other acute phase
proteins, ultimately causing neurodegeneration [1,2]. In
accordance with this view, long-term use of nonsteroidal
anti-inflammatory drugs (NSAIDs) reduced the risk of AD
and delayed its onset [3-8]. Overexpression of mutant
forms of amyloid β-protein precursor (APP) in the brains
of transgenic mice produced amyloid plaques surrounded
by activated microglia and reactive astrocytes and upregu-
lated interleukin (IL)-1, IL-6 and tumor necrosis factor
(TNF)-α, which resembled the alterations found in
patients with AD [9]. When Tg2576 mice, an AD mouse
model, overexpressing a mutant form of APP were treated
with an NSAID, ibuprofen, the mice improved in open
field activity and had reductions in levels of IL-1β, reactive
astrocytes and Aβ load [10,11]. The deletion of the TNF
type 1 death receptor gene in APP23 transgenic mice,
another transgenic mouse model of AD, inhibited Aβ gen-
eration, decreased amyloid plaques and prevented learn-
ing and memory deficits [12]. The deletion of the
interferon (IFN)-γ receptor type I gene in Tg2576 mice
caused less gliosis and amyloid plaques. In IFN-γ receptor
wild-type Tg2576 mice, IFN-γ elicited TNF-α secretion
resulting in upregulation of β-site APP-cleaving enzyme
(BACE1) in astrocytes, which caused an increase in Aβ
production. Additionally, upregulation of IFN-γ and TNF-
α suppressed Aβ degradation by microglia in the latter
mice [13]. These observations support the notion that
upregulation of proinflammatory cytokines and activa-
tion of glial cells promote the disease progression.
Recently, however, the reports of the potential beneficial
effects of innate immune responses in AD are increasing.
Activation of cultured microglia with toll-like receptor 2
(TLR2), TLR4, or TLR9 ligand markedly boosted ingestion
of Aβ [14-17]. An acute injection of lipopolysaccharide
(LPS, a TLR4 ligand) in the hippocampus reduced Aβ load
in an AD transgenic model [18] and microglial activation
is required for the LPS-induced reduction of Aβ load [19].
Accumulation of Aβ in the brain of an AD mouse model
triggered chemoattraction of bone marrow-derived cells
(microglia) that restricted amyloid deposits in the brain
[20]. Upon activation with LPS, bone marrow-derived
microglia decreased Aβ load in the brain of an AD mouse
model [21]. Mononuclear cells from normal subjects were
able to clear Aβ from the sections of AD brain but those
from AD patients were not. Furthermore, Aβ upregulates
expression of β-1,4-mannosyl-glycoprotein 4-β-N-
acetylglucosaminyltransferase (MGAT3) and TLRs in
mononuclear cells from normal subjects, whereas these
genes were down-regulated in cells from AD patients [22],
suggesting immune defects in AD patients. The deletion of
the CCR2 [a receptor for monocyte chemoattractant pro-
tein-1 (MCP-1 or CCL2)] gene in Tg2576 mice reduced
CD11b immunoreactive microglia in TLR4m and TLR4w AD  mice Figure 1
CD11b immunoreactive microglia in TLR4m and TLR4w AD 
mice. The frozen sections of cerebral cortices from TLR4m 
(A and B) and TLR4w (C and D) AD mice were stained with 
anti-CD11b antibody. Scale bars are 50 μm in A and C, and 
10 μm in B and D. The middle images (B and D) are a high 
magnification of the areas indicated by the squares in the top 
images (A and C). CD11b immunoreactive area percentages 
of TLR4m and TLR4w AD mice were shown as a bar graph 
(means ± SE, * P < 0.05) (E). Approximately 15 fields of the 
cerebral cortex (0.5 to 1 mm2 each, using a 10× objective and 
1× eyepiece lens) from 4 – 5 coronal brain sections, each 
separated by more than 240 μm interval, from each mouse 
were analyzed. TLR4m and TLR4w represent TLR4m and 
TLR4w AD mice, respectively.Journal of Neuroinflammation 2008, 5:23 http://www.jneuroinflammation.com/content/5/1/23
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the number of microglia and impaired Aβ clearance in the
brain [23]. Overexpression of C3 inhibitory soluble com-
plement receptor-related protein inhibited C3 in the brain
of an AD mouse model, decreased microglial activation
and increased Aβ deposition and neurodegeneration [24].
Overproduction of transforming growth factor (TGF)-β1
in an AD mouse model resulted in a vigorous microglial
activation that was accompanied by at least a 50% reduc-
tion in Aβ load [25]. Overexpression of IL-1β in the hip-
pocampus of APPswe PS1dE9 mouse model of AD [26]
activated microglia and astrocytes, upregulated expression
of TNF-β and IL-6 and decreased amyloid plaques [27].
These reports suggest that neuroinflammation found in
AD brain is beneficial and that activation of microglia and
astrocytes as well as upregulation of cytokines and chem-
okines can be therapeutic.
TLRs function as pattern-recognition receptors in the
innate immune system [28]. Activated phagocytes and tis-
sue dendritic cells through TLR signaling respond to path-
ogens and damaged host cells by secreting chemokines
and cytokines and express the co-stimulatory molecules
needed for protective immune responses, efficient clear-
ance of damaged tissues and adaptive immunity [29-31].
Microglia is the phagocyte in the central nervous system
and activated by a number of TLR ligands [32,33]. We pre-
viously demonstrated that an AD mouse model (Mo/Hu
APPswe PS1dE9 mice) homozygous for a destructive
mutation of TLR4 (TlrLps-d/TlrLps-d) had increases in diffuse
and fibrillar Aβ deposits as well as buffer-soluble and
insoluble Aβ in the brain as compared with a TLR4 wild-
type AD model mice [17]. Because induction of TLR sign-
aling activates microglia and upregulates cytokines and
chemokines, in the present study, we investigated the
roles of TLR4 in activation of microglia and astrocytes as
well as upregulation of cytokines and chemokines in the
AD mouse model. Activation of microglia and astrocytes
was determined by immunohistochemistry and immuno-
blotting. Levels of cytokines and chemokines were quan-
tified by multi-plex cytokine array.
Methods
Animals
A pathogen-free transgenic line of AD mouse model, Mo/
Hu APPswe PS1dE9 mice [26], was obtained from Jackson
Laboratory (Bar Harbor, ME) and maintained by crossing
transgenic males with B6C3F1 females that were pur-
chased from Jackson Lab, also. C3H/HeJ mice are highly
susceptible to Gram-negative infection and resistant to
bacterial lipopolysaccharide (LPS) due to a destructive
mutation of the TLR4 gene (TlrLps-d). The genotyping for
the APPswe transgene was performed by the PCR-based
method provided by the Jackson Lab. The TLR4 genotype
was determined by PCR followed by restriction enzyme
digestion with Nla III as described previously [17]. The
transgenic mice express chimeric mouse/human APP with
the double mutations (K670N and M671L) and human
PS1 with a deletion of exon 9 found in familial AD
patients. In this study, four experimental groups of 13–15
month-old mice which differed in the TLR4 gene and Mo/
Hu APPswe PS1dE9 transgene were used. The four experi-
mental groups were (1) homozygous TLR4 mutant Mo/
Hu APPswe PS1dE9 transgenic mice (n = 8), designated
here as TLR4m AD mice for simplicity, (2) TLR4 wild-type
transgenic mice (n = 10), designated as TLR4w AD mice,
(3) homozygous TLR4 mutant non-transgenic littermates
(n = 9), designated as TLR4m non-AD mice and (4) TLR4
wild-type non-transgenic mice (n = 9), designated as
TLR4w non-AD mice.
Brain tissue lysate preparation
Mice were sacrificed by lethal injection of pentobarbital
and the brains were quickly removed. After removing the
cerebellums, the left hemispheres were processed for pro-
tein array and immunoblot analyses. The left cerebrum
was lysed using the Bio-Plex cell lysis kit (Bio-Rad, Her-
cules, CA). Briefly, the cerebrum was rinsed with the cell
wash buffer and cut into 3 × 3 mm pieces. The sample was
transferred to a Dounce homogenizer on ice and homog-
enized in the lysis buffer containing proteinase inhibiters.
Then the ground tissue sample was transferred to a clean
Levels of CD11b and GAPDH in the cerebral tissue lysates  were determined by immunoblotting using anti-CD11b and  anti-GAPDH antibodies, respectively Figure 2
Levels of CD11b and GAPDH in the cerebral tissue lysates 
were determined by immunoblotting using anti-CD11b and 
anti-GAPDH antibodies, respectively. The bar graph repre-
sents densitometric quantification of CD11b after normaliza-
tion with GAPDH (means ± SE). The mean of CD11b levels 
in TLR4m AD mice is greater than that in TLR4w AD mice 
but not statistically significant. Lane 1 through 4 are tissue 
lysates from TLR4m AD mice and lane 5 through 9 are from 
TLR4w AD mice.Journal of Neuroinflammation 2008, 5:23 http://www.jneuroinflammation.com/content/5/1/23
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microcentrifuge tube and frozen at -80°C. After thawing,
the sample was sonicated on ice for 30 seconds. The sam-
ple was centrifuged at 4,500 g for 10 minutes at 4°C, and
the supernatant was collected for the protein array and
immunoblotting.
Immunoblotting and densitometric analysis
Immunoblot analysis was used to quantify cerebral
CD11b, CD45 and glial fibrillary acidic protein (GFAP) in
AD mice. Protein concentrations of brain lysates were
determined by Bio-Rad Protein Assay (Bio-Rad). Five
micrograms of total protein from each sample were
applied to 10–20% Tris-HCl gradient SDS-PAGE and elec-
trotransferred to polyvinylidine difluoride (PVDF) mem-
branes (Millipore, Bedford, MA). The membranes were
blocked by phosphate buffered saline (PBS) containing
5% non-fat dried milk (w/v), 0.02% sodium azide, and
0.02% Tween 20 for 1 hr at room temperature, incubated
at 4°C overnight with primary antibodies CD11b (Sero-
tec, MCA711, Raleigh, NC) for detection of activated
microglia, CD45 (Serotec, MCA1031G) for detection of
migratory leukocytes or GFAP (Dako, Demark) for reac-
tive astrocytes and visualized by the western lighting
chemiluminescence reagent plus (Perkin Elmer, Boston,
MA) according to the manufacturer's protocol. The mem-
branes were reprobed with monoclonal antibody against
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(Chemicon, Temecula, CA). The optical densities of
CD11b, CD45, GFAP and GAPDH bands from the mem-
branes were determined by densitometric scanning using
a HP Scanjet G3010 Photo Scanner and HP Photosmart
Software. The optical density of each protein band was
divided by that of the GAPDH band on the same lane
from the same membrane for normalization. The ratios
were expressed as mean ± standard error. Intergroup dif-
ferences were assessed by analysis of variance (ANOVA)
and two-tailed Student's t-test. P < 0.05 was considered
statistically significant.
Cytokine/chemokine microarray
Cerebral tissue lysates were prepared and their protein
concentrations were determined as described above. Lev-
els of cytokines and chemokines in the cerebral tissue
lysates were determined by the bead-based suspension
microarray technology (AssayGate, Ijamsville, MD) [34].
The threshold of detection was determined by adding two
standard deviations to the mean fluorescence intensity of
twenty zero standard (background) replicates. The mini-
mum detectable concentrations were 3.6 pg/ml for IL-1α,
3.8 pg/ml for IL-1β, 2.3 pg/ml for IL-2, 2.5 pg/ml for IL-3,
4.3 pg/ml for IL-4, 1.3 pg/ml for IL-6, 8.2 pg/ml for IL-10,
11 pg/ml for IL-12 (p40), 3.5 pg/ml for IL-12(p70), 9.2
pg/ml for IL-17, 6.6 pg/ml for granulocyte macrophage
colony-stimulating factor (GM-CSF), 2.3 pg/ml for IFN-γ,
16 pg/ml for TGF-β1, 3.7 pg/ml for TNF-α, 2.5 pg/ml for
MCP-1, 1.3 pg/ml for macrophage inflammatory protein
(MIP)-1α and 3.1 pg/ml MIP-1β. The results were
expressed in picograms per milligram of brain protein and
analyzed by ANOVA and two-tailed Student's t-test using
SigmaStat for Windows Version 3.00. P < 0.05 was consid-
ered statistically significant.
CD45-immunoreactive cells in TLR4m and TLR4w AD mice Figure 3
CD45-immunoreactive cells in TLR4m and TLR4w AD mice. 
The frozen sections of cerebral cortices from TLR4m (A and 
B) and TLR4w (C and D) AD mice were stained with anti-
CD45 antibody. Scale bars are 50 μm in A and C, and 10 μm 
in B and D. The middle images (B and D) are a high magnifica-
tion of the areas indicated by the squares in the top images 
(A and C). CD45 immunoreactive area percentages of 
TLR4m and TLR4w AD mice were shown as a bar graph 
(means ± SE) (E). Approximately 15 fields of the cerebral 
cortex (0.5 to 1 mm2 each, using a 10× objective and 1× eye-
piece lens) from 4 – 5 coronal brain sections, each separated 
by more than 240 μm interval, from each mouse were ana-
lyzed. TLR4m and TLR4w represent TLR4m and TLR4w AD 
mice, respectively.Journal of Neuroinflammation 2008, 5:23 http://www.jneuroinflammation.com/content/5/1/23
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Immunohistochemistry
Frozen sections (5 μm thickness) were prepared and sub-
jected to the immunoperoxidase method. Endogenous
peroxidase was eliminated by treatment with 3% H2O2/
10% methanol Tris-buffered saline (TBS) for 20 min at
room temperature. After washing with water and 0.1 M
TBS (pH 7.4), slides were blocked with 2% bovine serum
albumin (BSA) and 2% goat serum in 0.1% triton-X-100
TBS (TBST) buffer for 60 min at room temperature to pre-
vent non specific protein binding. Then the slides were
incubated with primary antibody CD11b (1:200), CD45
(1: 1000), or GFAP (1:1000) in 2% BSA, 2% goat serum
TBST overnight at 4°C. The sections were rinsed in 0.1 M
TBST containing 0.1% BSA and incubated with bioti-
nylated secondary antibody anti-rat IgG (1:200) for
CD11b, anti-rat IgG (1:1500) for CD45 or anti-rabbit IgG
(1:1000) for GFAP in 2% BSA, 1% goat serum TBST for 1
h at room temperature. Finally, the avidin biotin peroxi-
dase method using 3,3'-diaminobenzidine as a substrate
(Vector, Burlingame, CA) was performed according to
manufacturer's protocol. For the negative control, slides
were processed without primary antibody.
Histomorphometry for quantification of activated micro-
glia and reactive astrocytes was performed using an
OLYMPUS IX71 microscope, OLYMPUS DP70 digital
camera and the Image Pro Plus v4 image analysis software
(Media Cybernetics, Silver Spring, MD) capable of color
segmentation and automation via programmable macros.
Four to five coronal brain sections, each separated by
more than 240 μm interval, from each mouse were ana-
lyzed. All brain sections contained both cerebral cortex
Reactive astrocytes in TLR4m AD mice increase compared  to TLR4w AD mice by immunohistochemistry Figure 5
Reactive astrocytes in TLR4m AD mice increase compared 
to TLR4w AD mice by immunohistochemistry. The frozen 
sections of cerebral cortices from TLR4m (A and B) and 
TLR4w (C and D) AD mice were stained with anti-GFAP 
antibody. Scale bars are 50 μm in A and C, and 10 μm in B 
and D. The middle images (B and D) are a high magnification 
of the areas indicated by the squares in the top images (A and 
C). GFAP immunoreactive area percentages of TLR4m and 
TLR4w AD mice were shown as a bar graph (means ± SE, 
**P < 0.001) (E). Approximately 15 fields of the cerebral cor-
tex (0.5 to 1 mm2each, using a 10× objective and 1× eyepiece 
lens) from 4 – 5 coronal brain sections, each separated by 
more than 240 μm interval, from each mouse were analyzed. 
TLR4m and TLR4w represent TLR4m and TLR4w AD mice, 
respectively.
Levels of CD45 and GAPDH in the cerebral tissue lysates  were determined by immunoblotting using anti-CD45 and  anti-GAPDH antibodies, respectively Figure 4
Levels of CD45 and GAPDH in the cerebral tissue lysates 
were determined by immunoblotting using anti-CD45 and 
anti-GAPDH antibodies, respectively. The bar graph repre-
sents densitometric quantification of CD45 after normaliza-
tion with GAPDH (means ± SE). The mean of CD45 levels in 
TLR4m AD mice is greater than that in TLR4w AD mice but 
not statistically significant. Lane 1 through 4 are tissue lysates 
from TLR4m AD mice and lane 5 through 9 are from TLR4w 
AD mice.Journal of Neuroinflammation 2008, 5:23 http://www.jneuroinflammation.com/content/5/1/23
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and hippocampus. Consecutive 4 pictures of the cerebral
cortex with no overlaps, starting from the midline were
taken from each brain section using a 10× objective and
1× eyepiece lens. Pictures in which folded tissues were
found were discarded. Thus, approximately 15 pictures of
the cerebral cortex from each mouse were analyzed. The
area of the cerebral cortex in the pictures varied from
approximately 0.5 mm2 to 1 mm2. CD11b, CD45 and
GFAP stained areas were expressed as a percentage of total
cerebral cortex examined. Data were expressed as mean ±
standard error as a bar graph. Intergroup differences were
assessed by ANOVA and two-tailed Student's t-test. P <
0.05 was considered statistically significant.
Results
Activated microglia
Activated microglia were analyzed for expression of
CD11b (Mac-1) by immunohistochemistry. Representa-
tive micrographs from the cerebral cortex of AD mice were
shown in Fig. 1 A through D. Morphometric analysis of
the CD11b immunostaining revealed that the cerebral
cortex of TLR4m AD mice (1.10 ± 0.18%) had greater
microglial immunoreactivity than TLR4w AD mice (0.45
± 0.10%, P = 0.021) (Fig. 1E). CD11b immunoreactivity
in the brains of TLR4m and TLR4w non-AD mice was
unremarkable (data not shown). Microglial activation
was further determined by immunoblot analysis (Fig. 2).
Expression levels of CD11b in the cerebral tissue lysates
from TLR4m AD mice were on average higher than those
from TLR4w AD mice, which were not statistically signifi-
cant due to large variances (Fig. 2).
Migratory leukocytes
The common leukocyte antigen, CD45, was used to assess
the invasion of the brain by blood-derived leukocytes. The
cerebral cortex of TLR4m and TLR4w AD mice was immu-
nostained with anti-CD45 antibody (Fig. 3 A through D).
No significant difference was observed between the two
groups: 3.74 ± 0.19 and 3.54 ± 0.12% for TLR4m and
TLR4w AD mice, respectively (P = 0.37) (Fig. 3E). CD45
immunoreactivity in the brains of TLR4m and TLR4w
non-AD mice was unremarkable (data not shown). The
common leukocyte antigen in the cerebral tissue lysates
was further determined by immunoblot analysis (Fig. 4).
There was no difference between TLR4m and TLR4w AD
mice in expression levels of CD45 (Fig. 4).
Reactive astrocytes
Reactive astrocytes in the brains of TLR4m and TLR4w AD
mice were detected by immunohistochemistry using an
antibody against an astrocyte marker, GFAP (Fig. 5A
through 5D). Morphometric analysis indicated that the
cerebral cortex of TLR4m AD mice (1.20 ± 0.07%) had a
greater degree of astrocytosis compared with TLR4w AD
mice (0.61 ± 0.08%, P = 0.0006) (Fig. 5E). Astrocyte
immunoreactivity for GFAP in the cortex of non-AD mice
was unremarkable (data not shown). Immunoblot analy-
sis was also used to determine GFAP expression levels
(Fig. 6). Densitometric scanning of the immunoblot con-
firmed that GFAP expression levels in the cerebral tissue
lysates from TLR4m AD mice were higher than those from
TLR4w AD mice (P = 0.016) (Fig. 6). Thus, astrocytosis in
TLR4m AD mice was greater than that in TLR4w AD mice.
These results are in agreement with our previous report
that Aβ load in the cerebral cortex of TLR4m AD mice is
greater than that of TLR4w AD mice [17].
Levels of cytokines and chemokines
Levels of cytokines and chemokines in the cerebral
extracts from the four experimental groups of mice were
determined by multiplex cytokine/chemokine array anal-
ysis using the bead-based array technology [34].
Cytokines included IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-6, IL-
10, IL-12 (p40), IL-12(p70), IL-17, GM-CSF, IFN-γ, TGF-
β1, and TNF-α. Chemokines determined were MCP-1,
MIP-1α and MIP-1β. IL-3 and IL-4 in the cerebral tissue
lysates were less than 2.5 and 4.3 pg/ml, respectively,
which are the minimum detectable levels. Therefore, IL-3
and IL-4 were omitted from analysis. The levels of these
cytokines and chemokines are presented as bar graphs in
Fig. 7 and 8. Levels of IL-1β, IL-10, IL-17 and TNF-α
increased in the cerebrum of TLR4w AD mice compared to
TLR4w non-AD mice (P = 0.029, 0.013, 0.031 and 0.001,
Levels of GFAP and GAPDH in the cerebral tissue lysates  were determined by immunoblotting using anti-GFAP and  anti-GAPDH antibodies, respectively Figure 6
Levels of GFAP and GAPDH in the cerebral tissue lysates 
were determined by immunoblotting using anti-GFAP and 
anti-GAPDH antibodies, respectively. The bar graph repre-
sents densitometric quantification of GFAP after normaliza-
tion with GAPDH (means ± SE). GFAP levels in TLR4m AD 
mice are greater than those in TLR4w AD mice (*P < 0.05). 
Lane 1 through 4 are tissue lysates from TLR4m AD mice 
and lane 5 through 7 are from TLR4w AD mice.Journal of Neuroinflammation 2008, 5:23 http://www.jneuroinflammation.com/content/5/1/23
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respectively) (Fig. 7). There were no significant differences
in the other cytokines and chemokines between these
TLR4w groups. Levels of MIP-1α increased in TLR4m AD
mice compared to TLR4m non-AD mice (P = 0.006) (Fig.
8). There were no significant differences in any of the
other cytokines and chemokines between these TLR4m
groups. Levels of TNF-α and MIP-1β in TLR4w AD mice
were higher than those in TLR4m AD mice (P = 0.014 and
0.019, respectively). There were no significant differences
in the other cytokines and chemokines between these
transgenic groups. Although levels of many cytokines
such as IL-1, IL-2, IL-6, IL-10, IL-12, IL-17 and TGF-β1 in
TLR4m non-AD mice on average are higher than those in
TLR4w non-AD mice, the differences are not statistically
significant. Levels of TNF-α in TLR4m non-AD mice, how-
ever, were higher than those in TLR4w non-AD mice (P =
0.048), suggesting compensatory upregulation of some
cytokines in TLR4m mice.
Discussion
Neuroinflammation characterized by increases in acti-
vated microglia and cytokines is thought to modulate the
AD progression [1,2,35-37]. Such neuroinflammatory
changes in AD are partly recapitulated in transgenic ani-
mal models of AD [9]. Here we demonstrated that levels
of IL-1β, IL-10, IL-17 and TNF-α increased in the cere-
brum of TLR4w AD mice compared to TLR4w non-AD
mice. The levels of such cytokines in TLR4m AD mice were
not different from those in TLR4m non-AD mice. These
results indicate that TLR4 signaling mediates Aβ-induced
upregulation of IL-1β, IL-10, IL-17 and TNF-α in TLR4w
AD mice. It has been shown that fibrillar Aβ interacted
with CD14 (TLR2 and TLR4 accessory protein) and was
phagocytosed by cultured microglia and monocytes,
resulting in activation of the cells as well as increased
secretion of cytokines [38,39]. Aggregated Aβ failed to
activate cultured microglia from TLR4m C3H/HeJ mice
resulting in a diminished release of IL-6, TNF-α and nitric
oxide compared to microglia from TLR4w C3H/HeN mice
[40]. TLR4 neutralizing antibody also blocked Aβ-induced
activation of human monocytes [40]. Upregulation of
TLR4 and the association of CD14 with microglia in the
brains of AD patients were demonstrated by immunohis-
tochemistry [38,40]. We also found TLR4 upregulation in
activated microglia which were intimately associated with
Aβ deposits in Tg2576 mice (data not shown). These find-
ings suggest that aggregated Aβ can induce activation of
microglia and upregulation of certain cytokines through
TLR4 signaling.
IL-1β, IL-10, IL-17 and TNF-α were upregulated in the
brains of AD mice in a TLR4-dependent manner. As dem-
onstrated by many investigators, expression of IL-1β and
TNF-α is induced in cultured microglia and astrocytes in
response to Aβ treatment [2,37]. Many investigators
reported upregulation of IL-1β and TNF-α in AD mouse
models and AD patients although some reports presented
controversial data [2,9,37]. Upregulation of IL-10 was
also found in tissue samples from AD mouse models and
AD patients [41-43]. Because cytokines regulate the inten-
sity and duration of immune responses [44] and because
overexpression of IL-1β and TGF-β reduced Aβ load in the
brains of AD mouse models, upregulation of some of
these cytokines might have contributed to reducing Aβ
load in TLR4w AD mice [17].
To the best of our knowledge, upregulation of IL-17 has
not been reported in tissue samples from AD mouse mod-
Levels of cerebral cytokines and chemokines in TLR4m AD  and non-AD mice at the age of 13–15 months Figure 8
Levels of cerebral cytokines and chemokines in TLR4m AD 
and non-AD mice at the age of 13–15 months. Levels of 
cytokines and chemokines in the cerebral tissue lysates were 
determined by multiplex cytokine/chemokine array analysis. 
Hatched and open bars represent levels of cytokines and 
chemokines in TLR4m AD and non-AD mice, respectively. 
Mean concentrations ± SE are expressed in picograms per 
milligram of brain protein. *P < 0.05.
Levels of cerebral cytokines and chemokines in TLR4w AD  and non-AD mice at the age of 13–15 months Figure 7
Levels of cerebral cytokines and chemokines in TLR4w AD 
and non-AD mice at the age of 13–15 months. Levels of 
cytokines and chemokines in the cerebral tissue lysates were 
determined by multiplex cytokine/chemokine array analysis. 
Hatched and open bars represent levels of cytokines and 
chemokines in TLR4w AD and non-AD mice, respectively. 
Mean concentrations ± SE are expressed in picograms per 
milligram of brain protein. *P < 0.05, **P = 0.001.Journal of Neuroinflammation 2008, 5:23 http://www.jneuroinflammation.com/content/5/1/23
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els and AD patients. IL-17 is a proinflammatory cytokine
produced from Th17 T cells that develop from a lineage
distinct from the T helper-type 1 and 2 lineages [45]. IL-17
has been demonstrated to play important roles in the
pathogenesis of autoimmune diseases such as multiple
sclerosis and its animal models, experimental autoim-
mune encephalomyelitis [46-48]. Upon stimulation with
IL-1β, IL-17 is produced by microglia, also [49]. There-
fore, upregulation of IL-17 may be due to increased levels
of IL-1β in the brains of TLR4w AD mice. The role of IL-17
in the pathogenesis of AD remains to be investigated.
Activated microglia and reactive astrocytes are closely
associated with fibrilar Aβ deposits but are rarely found in
immediate proximity to diffuse Aβ deposits [9]. TLR4m
AD mice at 14–16 months of age showed an increase in
fibrillar Aβ deposits compared to TLR4w mice [17].
Immunoreactivity for CD11b and GFAP, markers for acti-
vated microglia and astrocyte, respectively, increased in
13–15 month-old TLR4m AD mice compared to TLR4w
AD mice. On the other hand, immunoreactivity for CD45
(migratory leukocytes) in TLR4m AD mice was not differ-
ent from that in TLR4w AD mice. In CCR2-deficient or C3
inhibitor-overexpressing mice, however, an increase in Aβ
levels in the brain was associated with a decrease in micro-
glial cells [23,24]. Overexpression of TGF-β1 or IL-1β
increased activated microglia and reduced Aβ load in the
brains of AD mouse models [24,27]. Therefore, we
expected less activated microglia and more Aβ load in
TLR4m AD mice compared to TLR4w AD mice. The rea-
sons for this discrepancy are not clear. This discrepancy,
however, may be due to use of CD11b as a marker for acti-
vated microglia because microglia at distinct activation
states differentially express several activation markers
[9,19]. Alternatively, an acute state of activated microglia
needs to be investigated to observe less activated micro-
glia in TLR4m mice because AD mice develop amyloid
deposits as early as 4–5 months of age [26,50]. Different
aggregation states of Aβ react with multiple cell surface
proteins/receptors other than CD14/TLR4 [51]. Such pro-
teins/receptors may activate microglia in a chronic state
without the beneficial effects. We are currently investigat-
ing activation of microglia and expression of cytokines in
TLR4m AD mice at younger ages.
Conclusion
In summary, we found upregulation of IL-1β, IL-10, IL-17
and TNF-α in TLR4w AD mice compared to non-AD mice.
Such upregulation was not observed in TLR4m AD mice.
Our results suggest that TLR4 signaling may be involved in
the AD progression through upregulation of certain
cytokines. Because IL-1β and TNF-α can modulate the AD-
like pathology progression in AD mouse models, TLR4
signaling can be a new therapeutic target for AD.
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